ResearcherSichuan UniversityNo recent work listed

Wei Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3512-9288; OpenAlex author ID A5101963619. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper

Papers 1

Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13929 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shengyong Yang · 1 shared paper, 2019 · strength 0.09
- Paper Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. DOI 10.1111/cas.13929 ↗
Bing Peng · 1 shared paper, 2019 · strength 0.09
- Paper Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. DOI 10.1111/cas.13929 ↗
Linli Li · 1 shared paper, 2019 · strength 0.09
- Paper Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. DOI 10.1111/cas.13929 ↗
Lingwei Meng · 1 shared paper, 2019 · strength 0.09
- Paper Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma. DOI 10.1111/cas.13929 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.